rethinkTHC Search
Menu
Study breakdown

The endocannabinoid system plays a key role in nicotine addiction and could be targeted for smoking cessation

ReviewModerate evidence
The takeaway

The CB1 receptor antagonist rimonabant helped smokers quit in clinical trials, and newer approaches targeting other endocannabinoid components may provide similar benefits without psychiatric side effects.

Read this if you're interested in how the cannabinoid system relates to tobacco addiction.

Rimonabant helped smokers quit but was withdrawn due to side effects

What the researchers found

This review compiled evidence for the endocannabinoid system's involvement in nicotine addiction. The CB1 receptor inverse agonist rimonabant reduced nicotine-taking and nicotine-seeking in animal studies and improved smoking quit rates in randomized clinical trials.

However, rimonabant was removed from the market due to increased psychiatric side effects (depression, suicidality) in humans. This withdrawal prompted research into alternative ways to modulate the endocannabinoid system for smoking cessation.

The review highlighted newer approaches targeting FAAH (the enzyme that breaks down anandamide), MAGL (the enzyme that breaks down 2-AG), and other endocannabinoid system components. These approaches might modulate nicotine addiction pathways without the psychiatric risks associated with directly blocking CB1 receptors.

Why it matters

Smoking remains a leading cause of preventable death, and existing cessation medications have limited effectiveness. If endocannabinoid system modulation can help people quit smoking without the psychiatric risks of rimonabant, it could save many lives.

The numbers in context

Rimonabant improved quit rates in clinical trials. Removed from market due to psychiatric side effects. Multiple alternative endocannabinoid targets identified: FAAH, MAGL, and other components.

How the study worked

Narrative review of preclinical and clinical evidence for the endocannabinoid system's role in nicotine addiction, covering CB1 receptor antagonism, enzyme inhibition, and other modulatory approaches.

What this study cannot tell us

Narrative review without systematic methodology. Many alternative approaches are still preclinical. The transition from animal models to human clinical applications has proven difficult for endocannabinoid-based treatments.

How to read the evidence

Narrative review combining clinical trial evidence (rimonabant) with preclinical data on alternative approaches.

When this study was published

Published in 2015. Endocannabinoid-based smoking cessation research has continued.

The bigger picture

The rimonabant story illustrates both the promise and the pitfalls of cannabinoid-based medicine. The system is clearly involved in addiction, but blocking it too broadly causes serious problems. More targeted approaches are needed.

Questions still open

  • Which endocannabinoid targets offer the best balance of efficacy and safety for smoking cessation? Could FAAH inhibitors help smokers quit without psychiatric side effects? Would these approaches work for cannabis dependence as well?

Common questions

Can cannabinoid drugs help you quit smoking?
One cannabinoid drug (rimonabant) improved smoking cessation rates in clinical trials but was pulled from the market due to psychiatric side effects. Researchers are now exploring safer alternatives that target different parts of the endocannabinoid system.
Why does the endocannabinoid system affect nicotine addiction?
The endocannabinoid system interacts with dopamine reward pathways that nicotine hijacks. Modulating this system can reduce the rewarding effects of nicotine and decrease drug-seeking behavior, at least in animal models.

Read the original research

Role of the endogenous cannabinoid system in nicotine addiction: novel insights.

Frontiers in psychiatry, 6, 41

Citation

Gamaleddin, Islam Hany; Trigo, Jose M; Gueye, Aliou B; Zvonok, Alexander; Makriyannis, Alexandros; Goldberg, Steven R; Le Foll, Bernard. (2015). Role of the endogenous cannabinoid system in nicotine addiction: novel insights.. Frontiers in psychiatry, 6, 41. https://doi.org/10.3389/fpsyt.2015.00041

Explore the wider topic